Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $4.6 million.

  • Northwest Biotherapeutics' Cash & Equivalents rose 5515.48% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 5515.48%. This contributed to the annual value of $2.2 million for FY2024, which is 230.48% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Cash & Equivalents is $4.6 million, which was up 5515.48% from $4.3 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Cash & Equivalents high stood at $15.2 million for Q4 2021, and its period low was $1.4 million during Q2 2023.
  • Its 5-year average for Cash & Equivalents is $5.1 million, with a median of $4.3 million in 2025.
  • Per our database at Business Quant, Northwest Biotherapeutics' Cash & Equivalents surged by 87748.69% in 2021 and then plummeted by 7052.37% in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Cash & Equivalents (Quarter) stood at $15.2 million in 2021, then tumbled by 54.08% to $7.0 million in 2022, then tumbled by 69.48% to $2.1 million in 2023, then increased by 2.3% to $2.2 million in 2024, then surged by 109.66% to $4.6 million in 2025.
  • Its Cash & Equivalents stands at $4.6 million for Q3 2025, versus $4.3 million for Q2 2025 and $2.8 million for Q1 2025.